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Valsartan (VAL) is a highly selective blocker of the angiotensin II receptor that has been widely used 
in the treatment of hypertension. Active pharmaceutical ingredient compatibility with excipients 
(crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose and titanium dioxide) is 
usually evaluated in solid pharmaceutical development. Compatibility and stability can be evaluated 
by liquid chromatography. Studies were performed using binary mixtures of 1:1 (w/w) VAL/excipient; 
samples were stored under accelerated stability test conditions (40 °C at 75% relative humidity). The 
results indicate that VAL is incompatible with crospovidone and hypromellose, which reduced the VAL 
content and gave rise to new peaks in the chromatogram due to degradation products.
Uniterms: Valsartan/compatibility. Valsartan/stability. Hypertension/treatment. Differential Scanning 
Calorimetry/drug analysis. High performance liquid chromatography/quantitative analysis. Pharmaceutical 
formulations/quantitative analysis.. 
Valsartana (VAL) é um bloqueador altamente seletivo do receptor da angiotensina II, que tem sido 
amplamente utilizado para o tratamento da hipertensão. Testes de compatibilidade com excipientes 
usualmente empregados em formulações sólidas são utilizados no desenvolvimento de formulações 
sólidas. Neste trabalho, realizaram-se testes utilizando misturas binárias na proporção 1:1 (m/m) de 
VAL/excipiente e as amostras foram armazenadas em condições de estabilidade acelerada (40 °C em 
75% de umidade relativa). Os resultados obtidos indicam a incompatibilidade de VAL com crospovidona 
e hipromelose, através da redução do teor de VAL e a presença de novos picos no cromatograma 
provenientes de produtos de degradação.
Unitermos: Valsartana/compatibilidade. Valtasan/estabilidade. Hipertensão/tratamento. Calorimetria 
Exploratória Diferencial/análise de fármacos. Cromatografia líquida de alto desempenho/análise 
quantitativa. 
INTRODUCTION
Hypertension is a chronic medical condition that is 
the world’s leading cause of mortality (Lewington et al, 
2002; Lotufo, 2005), affecting people of varying ages and 
economic status. To minimize or prevent hypertension, 
adequate diet and physical exercise are recommended. 
Many different medicines can be used to treat high blood 
pressure, including angiotensin II receptor antagonists 
such as valsartan (VAL), also known as N-(1-oxopentyl)-
N-[2’-(1H-tetrazol- 5-yl) [1,1’-biphenyl]-4-yl]methyl]-
L-valine (Celebier et al., 2010). This medication is 
generally prescribed in high doses (approximately 40 to 
320 mg daily) for continuous use. Interactions between 
VAL and excipients can contribute to the formation of 
degradation products, which may potentially be toxic or 
alter bioavailability. Consequently, these interactions may 
affect the safety and efficacy of VAL in solid formulations.
Pre-formulation testing, an important step in the 
development of new products or the reformulation of 
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existing ones, includes the chemical characterization of the 
drug and analytical compatibility/stability tests (Gibson, 
2004). In pharmaceutical industry, an active pharmaceutical 
ingredient (API) is subjected to pre-formulation studies, 
which provide the necessary information for the 
development of a stable drug formulation with adequate 
bioavailability (Blasko et al., 2001).
A drug is rarely administered in isolation; in most 
cases, it is associated with a variety of adjuvants and 
excipients (diluents, disintegrants, lubricants) to ensure 
adequate absorption, to increase stability and to improve 
appearance. Although excipients are often considered 
inert, it is known that they can interact with APIs, changing 
their stability, absorption and bioavailability. Therefore, 
an effective pharmaceutical formulation depends on the 
selection of suitable excipients (Mura et al., 2005; Stulzer 
et al., 2008). To investigate the compatibility of the 
components of a formulation, techniques such as X–ray 
diffraction, infrared spectroscopy, high performance liquid 
chromatography (HPLC) and thermal analysis (especially 
differential scanning calorimetry (DSC)) are used 
(Almeida et al., 2010; Julio et al., 2012; Slavio et al., 2009; 
Verma et al., 2004). Differential scanning calorimetry is 
a fast and reliable technique for use in pharmaceutical 
compatibility tests (Júlio et al., 2012; Oliveira et al., 2011; 
Verma et al., 2005); however, only crystalline samples 
show a sharp and strong endothermic event related to 
melting. Amorphous (non-crystalline materials) do not 
show these endothermic events. Materials that exhibit 
fusion followed by decomposition (such as hydrochloride 
salts) are difficult to evaluate in this way and should be 
tested by non-thermal methods (Late et al., 2008; Liltorp 
et al., 2011). Thus, solid-state characterization of APIs 
should be performed before pre-formulation evaluation 
or compatibility studies. However, to ensure accurate 
and reliable results, it is necessary to determine the most 
appropriate and sensitive technique for a specific API 
through validated stability-indicating methods.
Another factor that should be considered in drug 
development is stability, which is evaluated through the 
detection of degradation products. The API is combined 
with the proposed excipients and submitted to an 
accelerated stability chamber, according to International 
Conference on Harmonization (ICH) methods. Humidity 
has significant effects on drugs if reactive species are 
present in the formulation, potentially leading to physical 
or chemical modification (such as hydrolysis or hydrate 
formation) (Adami, Waterman, 2005). Drug stability 
guidelines (Q1A-Q1F) require that formulation stability 
tests be performed under accelerated and long-term 
conditions (ICH, 2003). These tests provide information 
about drug shelf life and permit detection/quantification 
of degradation products.
The present study investigated the compatibility 
of VAL with excipients commonly used in solid 
pharmaceutical formulation. We also conducted 
accelerated stability tests following ICH recommendations 
using direct contact with humidity and heat. The 
chemical interactions of VAL in binary mixtures were 
investigated by HPLC. X-Ray diffraction, DSC and 
thermogravimetric (TG) data were also obtained during 
solid-state characterization of VAL.
MATERIAL AND METHODS
Samples and reagents
Valsartan (Dr. Reddys, India (batch AFEH002828)) 
and USP grade excipients (crospovidone, hypromellose, 
magnesium stearate, microcrystalline cellulose and 
titanium dioxide) were donated by Aché Pharmaceutical 
(Brazil). HPLC grade acetonitrile was obtained from 
JT Baker (USA); glacial acetic acid was obtained from 
Sigma-Aldrich (Brazil). De-ionized water for HPLC 
analysis was prepared using a Millipore Direct-Q 3UV 
water purification system (Millipore, France). Other 
reagents were of analytical grade and were used without 
further purification.
Accelerated stability study
Stability testing was performed using VAL alone and 
in binary mixtures with each excipient in a 1:1 (m/m) ratio. 
For stability studies, VAL and excipients were weighed in 
4 mL glass vials (n=3), homogenized using two stainless 
steel balls (3 mm) and then vortex-mixed for one minute 
at 25 Hz. After preparation, the steel balls were removed, 
and the samples were stored for one month in a stability 
chamber at 40±0.5 °C/75±1% relative humidity (RH) in 
open containers (direct contact with humidity). 
Differential Scanning Calorimetry Analysis (DSC)
Thermal analysis of VAL was conducted using 
a high sensitivity DSC calorimeter (model EXSTAR 
X-DSC7020, SII Nanotechnology Inc., Japan) equipped 
with a microscope. Samples (approximately 4 mg) were 
encapsulated in hermetically sealed aluminum pans. All 
experiments were performed under a nitrogen flow of 
50 mL min-1 at a heating rate of 10 °C min-1 from 20 to 
350 °C. An indium standard with purity of more than 
99.99% was used for temperature calibration.
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FIGURE 1 - DSC and TG curve of VAL.
Thermogravimetric Analysis (TG)
A TG curve was obtained employing a thermobalance 
(model SDT Q600, TA Instruments, USA) in a temperature 
range of 25 to 600 °C, using alumina crucibles containing 
samples of approximately 4 mg under a flow of N2 
(100 mL min-1) at a heating rate of 10 °C min-1. The TG/DTA 
equipment was calibrated using an indium standard for 
temperature and an alumina calibration weight for mass.
Powder X-ray diffraction (PXRD)
Diffractograms were obtained in a Powder X-ray 
diffractometer (model Ultima IV, Rigaku, Japan) using a 
CuKα tube (1.5418 Å) at a voltage of 40 kV and a current 
of 30 mA in the range of 5 to 55 (°2θ). 
High performance liquid chromatography (HPLC) 
The quantification of VAL in each mixture submitted 
at 40 ºC and 75% RH was performed using HPLC according 
to the relevant monograph in the US Pharmacopeia (USP 
32, 2009). The samples were prepared by diluting binary 
mixtures with the mobile phase (0.45 mg mL-1 of VAL), 
sonicating for 15 min and filtering through 0.45 µm filters 
before HPLC analysis. The HPLC system used in this 
work was composed of an online degasser (DGU-20A5), 
liquid chromatograph (LC-20AT), auto sampler (SIL-
20A), photodiode array (PDA) detector (SPD-M20A) set 
to 273 nm and LC Solutions software version 1.21 SP1 
(Shimadzu, Japan). Briefly, the pharmacopeia method 
involves isocratic elution with a Hypersil ODS C18 
column (Waters, USA) (5 μm, 3.0 mm x 12.5 cm) at 25 °C 
using a mobile phase of water, acetonitrile and glacial 
acetic acid (500:500:1). The injection volume was 10 μL 
and the flow rate was 0.4 mL min-1. After appropriate 
dilution, the samples were analyzed using HPLC and 
the VAL content determined from the calibration curve 
prepared over the expected range (0.1 to 0.9 mg mL-1).
RESULTS AND DISCUSSION
Analytical technique
VAL was characterized using both thermal analysis 
and PXRD. VAL showed two endothermic peaks at 
70.5 °C (ΔH= 4.04 J g-1) and 99.1 °C (ΔH= 8.09 J g-1) 
and an exothermic peak with Tonset = 165.3 °C related to 
the beginning of decomposition. The TG curve showed 
two principal mass reduction events, with DTG peaks at 
211.7 °C and 408.9 °C (Figure 1). Only the first endothermic 
event (70.5 °C) resulted in a mass reduction of 1.67% 
in the TG analysis, presumably due to residual solvents. 
The second endothermic event was investigated using 
imaging-DSC. The results are shown in Figure 2, indicating 
melting of VAL at Tonset = 94.2 °C and Tendset = 102.8 °C. In 
Figure 3, the powder X-ray diffractogram of VAL reveals 
FIGURE 2 – Imaging-DSC photomicrographs of VAL.
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no crystallographic peaks, suggesting that the material 
was amorphous. Hence, the VAL used in this study was 
amorphous and did not show any thermal events, preventing 
the use of DSC for compatibility evaluation.
Thermal analysis has the advantage of responding 
to analytes in an ambient environment suitable for the 
acceleration of degradation reactions. When such methods 
cannot be employed, non-thermal methods such as liquid 
chromatography or spectroscopy are the most sensitive 
and suitable techniques. However, there are no immediate 
reactions between the API and excipients when contact is 
established. Therefore, these methods must be combined 
with storage (humidity and heat) to accelerate degradation 
or API-excipient reactions.
Although liquid chromatography is considered slow 
due to the complexity of some samples, it is able to offer 
qualitative and quantitative indications of API degradation 
when stability-indicating methods are employed. Several 
FIGURE 3 - Powder X–ray diffractogram of VAL.
HPLC-UV methods for the determination of VAL have 
been described in the literature (Agrahari et al., 2009; 
Celebier et al., 2010; Krishnaiah et al., 2010) but have 
not been used to test VAL’s stability and compatibility 
with excipients.
Stability and compatibility assay
The evaluation of the stability and compatibility 
of VAL and its binary mixtures after one month at 40 °C 
and 75% RH was conducted using the HPLC-UV method 
described in the relevant USP monograph (USP 32, 
2009). The response was linear within the range studied 
(R² = 0.9882). The HPLC-UV method for quantitation 
of VAL can detect thermal degradation and chemical 
interactions with excipients, which decrease the 
concentration of VAL (Table I).
The chromatograms for VAL before and after the 
stability study are illustrated in Figure 4. In this analysis, 
FIGURE 4 - HPLC chromatogram of VAL before and after 1 
month at 40 ºC and 75% RH.
TABLE I - HPLC data from VAL and binary mixtures after one month at 40 ºC and 75% RH (n= 3)
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VAL + Magnesium stearate
VAL + Microcrystalline cellulose




































a Observed concentration = (Area + 0.450 × 106)/ 2 × 107
b % of degradation = (Initial concentration - Final concentration/ Initial concentration) x 100
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no alteration in the chromatographic profile was observed 
between samples; there were no peaks from degradation 
products. The reduction in VAL concentration was quite 
small (approximately 0.36%, see Table I), which indicates 
that there was no significant change in the amount of API 
after the accelerated stability assay. Therefore, moisture 
and heat are not important factors in promoting the 
degradation of VAL in isolation.
The chromatograms of VAL and binary mixtures 
(microcrystalline cellulose, titanium dioxide and 
magnesium stearate) are shown in Figure 5. No alteration 
in peak area was detected, indicating that these excipients 
have sufficient compatibility for use in solid formulations 
of VAL.
Microcrystalline cellulose is widely used in 
pharmaceutical formulations as a binder/diluent; its 
compatibility has been studied in several solid formulations 
(Bazzo et al., 2005; Ceschel et al., 2003; Stulzer et al., 
2008). Magnesium stearate is employed as a lubricant; it is 
incompatible with several drugs (Daniel et al., 2013; Tita et 
al., 2011; Handbook of Pharmaceutical Excipients, 2006) 
but is compatible with others (Verma et al., 2004; 2005). 
Similar behavior was obtained in this study: no chemical 
interaction occurred in this binary mixture.
Degradation of VAL (approximately 9.17%, 
Table I) occurs when it is mixed with crospovidone, a 
tablet disintegrant. In addition to the decrease in drug 
content, formation of a possible degradation product 
was observed, presumably due to chemical interactions 
between crospovidone and VAL (Figure 6). This finding 
suggests that crospovidone is incompatible with VAL 
under these conditions (high humidity and temperature). 
In previous reports (Ahuja et al., 2003) crospovidone, a 
cross-linked modified polyvinylpyrrolidone (PVP), was 
FIGURE 5 - HPLC chromatogram of VAL before storage and 
of binary mixtures with microcrystalline cellulose, titanium 
dioxide, and magnesium stearate after storage.
incompatible with several APIs, due to generation of 
hydrogen peroxide (Yue et al., 2009; Wu et al., 2011). 
Peroxides are reactive substances present in various 
excipients that can initiate radical chain reactions or react 
directly with drugs, inducing the formation of degradation 
products. A similar result was observed for the binary 
mixture of VAL with hypromellose (Figure 6). In this 
case, the concentration of VAL decreased and a new peak 
appeared in the chromatogram, which we attribute to a 
degradation product. Hydroxypropyl methycellulose, a 
coating agent and rate-controlling polymer for sustained 
release formulations, may react with the hydroxyl group 
of VAL (Dong et al., 2008).
Hypromellose and crospovidone degradation 
product peak areas are given in Table 1. These degradation 
products have not been identified or reported previously. 
Although VAL was incompatible with these two excipients, 
the final formulation would not be in direct contact with 
high humidity (75% RH). Furthermore, a wet granulation 
process must be avoided in VAL solid formulation.
These  resul t s  demonst ra te  tha t  exc ip ient 
compatibility testing is essential for stable formulation 
development and for choosing between dry or wet 
granulation processes, as well as for controlling the final 
humidity of the formulation.
CONCLUSION
Different techniques were used to evaluate the 
stability and compatibility of VAL with pharmaceutical 
excipients. The results confirmed that HPLC is suitable for 
the evaluation of amorphous VAL-excipient interactions 
in the first stage of formulation. Though more laborious, 
FIGURE 6 - HPLC chromatograms of VAL in binary mixtures 
with crospovidone and hypromellose (a and b are degradation 
products).
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HPLC is more reliable, due to the accurate results obtained 
using a pharmacopeia-validated stability-indicating method.
Based on the HPLC-UV results, most of the 
excipients tested (microcrystalline cellulose, titanium 
dioxide and magnesium stearate) were compatible with 
VAL. However, chemical interactions were inferred from 
a reduction in API concentration, and degradation products 
were detected when crospovidone or hypromellose was 
used. However, this study was performed using binary 
mixtures (1:1 w/w), while the ratio in a formulation might 
be lower, reducing the degradation rate. In the case of 
hypromellose, this excipient is part of the formulation 
coating; thus, there is less contact with the drug, and 
the incompatibility might not be significant in tablets. 
However, pre-formulation studies using binary mixtures in 
equal proportions (1:1) are a useful procedure to detect the 
formation of degradation products in a new formulation.
A non-thermal compatibility study of an active 
substance should be combined with stability and assay 
determination with various excipients to determine 
the most appropriate excipient. Moreover, the stability 
of the drug when combined with other components 
should be evaluated, thus ensuring a safe and effective 
pharmaceutical formulation.
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